Civica nabs trial partner as it forges ahead to create more affordable insulins
A nonprofit drug manufacturer is moving forward with plans to stem the rising tide of insulin costs in the US.
Utah-based Civica has selected German-based research organization Profil as its human clinical trial partner to support the development of Civica’s affordable insulins. Civica is planning to produce three insulin biosimilars – dubbed glargine, lispro and aspart – each of which will be available both in vials and pre-filled pens.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters